This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase 1a (All cohorts except Cohort D-4 and D-5) : Percentage of participants who experience a Dose Limiting Toxicity (DLT)
Timeframe: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)
Phase 1a (Cohort D-4 and D-5) : Percentage of adverse events and treatment-related adverse events.
Timeframe: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)
Phase 1b (Cohort B-n, D-n and E-n) : Objective Response Rate (ORR)
Timeframe: Through completion of treatment (estimated up to be 11 months)
Phase 1b (Cohort C-n): The 6-month PFS proportion by RECIST v1.1
Timeframe: Through completion of treatment (estimated up to be 11 months)